Progressive multifocal leukoencephalopathy and natalizumab - Unforeseen consequences

New England Journal of Medicine

Volumn 353, Issue 4, 2005, Pages 414-416

  Berger, Joseph R ^a   Koralnik, Igor J ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; NATALIZUMAB; MONOCLONAL ANTIBODY;

CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; CROHN DISEASE; CYTOTOXIC T LYMPHOCYTE; DEMYELINATION; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DRUG WITHDRAWAL; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; JC VIRUS; MONOTHERAPY; MULTIPLE SCLEROSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; BRAIN; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; LEUKOENCEPHALOPATHY; NOTE; PATHOLOGY;

ANTIBODIES, MONOCLONAL; BRAIN; CROHN DISEASE; DISEASE PROGRESSION; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OPPORTUNISTIC INFECTIONS;

EID: 22844438117     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe058122     Document Type: Editorial

References (18)

1. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74.
2. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81.
3. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8.
4. Tornatore C, Berger JR, Houff SA, et al. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol 1992;31:454-62.
5. Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004;127:1970-8.
6. Du Pasquier RA, Schmitz JE, Jean-Jacques J, et al. Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. J Virol 2004;78:10206-10.
7. Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998;4:59-68.
8. Antinori A, Cingolani A, Lorenzini P, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003;9:Suppl 1:47-53.
9. Rudick RA, Sandrock A. Natalizumab: alpha4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 2004;4:571-80.
10. Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. Neurology 1999;53:466-72.
11. Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 2003;9:Suppl 1:25-31.
12. Hall CD, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med 1998;338:1345-51.
13. Aksamit AJ. Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. J Neurovirol 2001;7:386-90.
14. Groothuis DR, Benalcazar H, Allen CV, et al. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. Brain Res 2000;856:281-90.
15. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003;71:115-23.
16. Weber T, Trebst C, Frye S, et al. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 1997;176:250-4.
17. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005;5:582-94. [Erratum, Am J Transplant 2005;5:839.]
18. Pfister LA, Letvin NL, Koralnik IJ. JC virus regulatory region tandem repeats in plasma and central nervous system isolates correlate with poor clinical outcome in patients with progressive multifocal leukoencephalopathy. J Virol 2001;75:5672-6.